4743.TWO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 08:30):

Stats
Dzisiejszy wolumen	1.51M
Średni wolumen	2.17M
Kapitalizacja rynkowa	71.79B
EPS	TWD0 ( 2024-03-05 )
Następna data zysków	( TWD0 ) 2024-05-09
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-48.02
ATR14	TWD0.185 (0.12%)

Wolumen Korelacja

Długi: -0.08 (neutral)

Krótki: 0.00 (neutral)

Signal:(35.335) Neutral

Oneness Biotech Co., Ltd. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oneness Biotech Co., Ltd. Korelacja - Waluta/Towar

-0.86
( strong negative )

0.55
( weak )

0.00
( neutral )

0.56
( weak )

-0.50
( weak negative )

-0.65
( moderate negative )

Oneness Biotech Co., Ltd. Finanse

Annual	2023
Przychody:	TWD86.78M
Zysk brutto:	TWD-381.69M (-439.82 %)
EPS:	TWD-2.91

FY	2023
Przychody:	TWD86.78M
Zysk brutto:	TWD-381.69M (-439.82 %)
EPS:	TWD-2.91

FY	2022
Przychody:	TWD1.07B
Zysk brutto:	TWD844.39M (79.24 %)
EPS:	TWD0.820

FY	2021
Przychody:	TWD65.77M
Zysk brutto:	TWD45.04M (68.49 %)
EPS:	TWD-1.060

Financial Reports:

No articles found.

Oneness Biotech Co., Ltd.

Oneness Biotech Co., Ltd engages in the research and development of new drugs, and sale of pharmaceutical and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis and systemic sclerosis; FB825, which is in Phase II clinical trial for treating atopic dermatitis, allergic diseases, and asthma; and FB918, a human monoclonal antibody, which is in pre-clinical stage for the treatment of allergic asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and sale of agricultural products. The company was incorporated in 2008 and is headquartered in Taipei City, Taiwan.